Panobinostat (LBH589)

For research use only. Not for use in humans.

Catalog No.S1030 Synonyms: NVP-LBH589

216 publications

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
USD 90 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Panobinostat (LBH589) has been cited by 216 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHWNE0yOCEQvF2= MkT5NE01KGR? MYPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVnsdYxsOjZ5MEK3PFQ>
HepG2 MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHXNVgxNTFyIN88US=> M1L3e|AuPCCm NWrXcZBRcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NETGXIszPjdyMke4OC=>
HT29 NGLKNodHfW6ldHnvckBCe3OjeR?= MXu1NOKhdk1? MXuyOE04OiCq NIrscpRqdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|IHHmeIVzKDR6wrDoxsA> NVjjfVRWOjZ5MEK3PFQ>
HepG2 M{nuT2Z2dmO2aX;uJGF{e2G7 MmnjOVDDqG6P NHP3fokzPC15MjDo MVLpcoR2[2WmIHHjeIl3[XSrb36gc4Yh[2G|cHHz[UA{KGGodHXyJFI1yqCqwrC= M3nqbFI3PzB{N{i0
HCC827 NXHYU|VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYC1M|cvPS9zMDDuUS=> NHvV[oc4OsLiaB?= NFXIZVBFVVOR NVPHZVFl\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= NHn2NVAzPjZ5NUS4OC=>
A549  MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjKO5J5OTBxMUWvNlAhdk1? MVK3NuKhcA>? MVPEUXNQ NYLHVFg2\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= NHe1elIzPjZ5NUS4OC=>
NCI-H460  NHPBVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmxNE8zOC9|MDDuUS=> M2fPRVczyqCq M4fsUWROW09? NYHTNnk6\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= NFHkVlgzPjZ5NUS4OC=>
J89GFP MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPmSG1UV8Li MXLFR|UxRTR7Lki1JOKyKDF{Lk[1JI5O NI[x[JczPjV4M{W2PC=>
THP89GFP MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\MZ5N1TE2VT9Mg NG\x[I5GSzVyPUG5MlM1KMLzIE[uOFMhdk1? NHO4SGQzPjV4M{W2PC=>
SK-NEP-1 NIrXSlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWCwMlAy6oDVMUCuNEDPxE1? M{Xae|I1KGh? NYTtWVlOTE2VT9Mg Mk\JTWM2OD15Nj6zOEBvVQ>? NV\SRnZ2OjZzN{[yNVk>
G401 NEfTU2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjKWZF4OC5yMfMAl|ExNjBizszN NXvCTm9JOjRiaB?= NVPybZNZTE2VT9Mg NEPpbJlKSzVyPUG0N{4xOiCwTR?= MmTYNlYyPzZ{MUm=
SK-NEP-1 MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NF3HS3c2OCCwTR?= NF\VUWcy6oDVNDDk NIP0OG5FVVORwrC= MWHy[YR2[2W|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MoPKNlYyPzZ{MUm=
G401 MnHyR4VtdCCYaXHibYxqfHliQYPzZZk> MnP6OVAhdk1? NHrzRnQy6oDVNDDk M1;OW2ROW00EoB?= Mly0doVlfWOnczDj[YxtKHO3co\peoFtKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz MoHtNlYyPzZ{MUm=
SK-NEP-1 NFuz[HBCeG:ydH;zbZMhSXO|YYm= NUjkVFRLPTBxMUCwJI5O M3HqbFI1KGh? NUHHdFNMTE2VT9Mg MmfobY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NUm1d4xEOjZzN{[yNVk>
G401 M4nTPGFxd3C2b4Ppd{BCe3OjeR?= NX[5N4FLPTBxMUCwJI5O MVyyOEBp MVnEUXNQyqB? MnnvbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXG3enRLOjZzN{[yNVk>
SK-NEP-1 M4PGNWZ2dmO2aX;uJGF{e2G7 NVm4NpgxPTBxMUCwJI5O NEWyeIwzPCCq Moe0SG1UV8Li M4DSXpNpd3e|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25? MlWxNlYyPzZ{MUm=
G401 M3rRXWZ2dmO2aX;uJGF{e2G7 NVT4Z2tSPTBxMUCwJI5O Mm\YNlQhcA>? MoezSG1UV8Li Mkntd4hwf3NidHjlJIlv\HWldHnvckBw\iCGTlGg[pJi\22nboTheIlwdg>? M3;W[|I3OTd4MkG5
SK-NEP-1 NV;hTZdiTnWwY4Tpc44hSXO|YYm= MUO1NE8yODBibl2= MojmNlQhcA>? NEW2O|RFVVORwrC= M164Solv\HWlZYOgZ4VtdCCleXPs[UBlcXOxcnTlduKh MoTVNlYyPzZ{MUm=
G401 NHvCcWJHfW6ldHnvckBCe3OjeR?= MUm1NE8yODBibl2= MoO0NlQhcA>? NIDzXGdFVVORwrC= MVfpcoR2[2W|IHPlcIwh[3mlbHWg[Il{d3KmZYNCpC=> NXviV5hZOjZzN{[yNVk>
RPMI 8226 MWTD[YxtKFO3co\peoFtKEG|c3H5 MYCyM|QwPiCwTR?= NFjwNVk1QOLCiXi= MWjpcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp NV7KRlZEOjZyMECyPVI>
OPM2 MnrKR4VtdCCVdYL2bZZidCCDc4PhfS=> MlexNk81NzZibl2= NUDIW3VsPDkkgJno NIj3XHdqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq MoH0NlYxODB{OUK=
U266 NHG3d3RE\WyuIGP1dpZqfmGuIFHzd4F6 Mk\INk81NzZibl2= M2\DfVQ56oDLaB?= MmPybY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? MYOyOlAxODJ7Mh?=
H929 MVvD[YxtKFO3co\peoFtKEG|c3H5 M{\m[FIwPC94IH7N NWfEeWYyPDkkgJno NXfMNlh3cW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= NVvaVnlsOjZyMECyPVI>
RPMI 8226  M4rpVGFxd3C2b4Ppd{BCe3OjeR?= NU\Td2V3POLCiX7N NYnoRpB4OjRxNEigbC=> MV;pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVz Mnf6NlYxODB{OUK=
HCC827 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVOxNEBvVQ>? M3f5clQ5KGh? NULPNmF7TE2VTx?= NEDINpFmdmijbnPld{BkcXOybHH0bY4he2Wwc3n0bZZqfHoEoB?= NX3HNWJvOjV7NES2NVc>
NCI-H23 Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jae|ExKG6P NYTPNHc3PDhiaB?= NWC0V3ZMTE2VTx?= M33TTYVvcGGwY3XzJINqe3CuYYTpckB{\W6|aYTpeol1gcLi NWnpdZQ5OjV7NES2NVc>
AML3 NGHBcIdHfW6ldHnvckBCe3OjeR?= MXmwMVEh|ryP NYrZTXVmOjUEoHi= MoKxbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MVeyOVYyOjl2MR?=
ML-1 MonRSpVv[3Srb36gRZN{[Xl? MmHCNE0yKM7:TR?= MmnYNlTDqGh? M{P1WIlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MoTMNlU3OTJ7NEG=
RPMI-8226vr10  MV3GeY5kfGmxbjDBd5NigQ>? MlqxNE0yKM7:TR?= M{P3RVI1yqCq M4TNcYlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NYDFb49IOjV4MUK5OFE>
ML-1 MWTGeY5kfGmxbjDBd5NigQ>? MUGxJO69VQ>? NGXObo8zPMLiaB?= NVO1UYVpcW6lcnXhd4V{KGOjc4Dhd4UuOyCjY4Tpeol1gSB2LX\vcIQ> NEHQV5QzPTZzMkm0NS=>
RPMI-8226vr10  NHrUZnRHfW6ldHnvckBCe3OjeR?= M2DBSFEh|ryP NHjv[owzPMLiaB?= M1zNcolv[3KnYYPld{Bk[XOyYYPlMVMh[WO2aY\peJkhOi53LX\vcIQ> Mn7UNlU3OTJ7NEG=
SK-N-BE (2) NFTTN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4CxN|I16oDLaB?= Ml\kTWM2OD1zMESuNQKBkcLz4pEJO{45KG6P MXqyOVMxQDlzNh?=
SK-N-BE (2), PAN  MK MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVuyOQKBkWh? M3ziUGlEPTB;MUC0MlDjiIoEsfMAjVcvQCCwTR?= NFfQZ|UzPTNyOEmxOi=>
SK-N-BE (2), MK  PAN M1O1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfjUI4zPOLCiXi= M{jFRWlEPTB;M{iyMlDjiIoEsfMAjVQ{NjJibl2= NHv4NJEzPTNyOEmxOi=>
SK-N-AS NULsVFZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULRW2t[OjUkgJno NEHUV|NKSzVyPUO3MlHjiIoEsfMAjVIvPCCwTR?= NI\3W3EzPTNyOEmxOi=>
SK-N-DZ NVrvN2x6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmSzNlTjiImq MoH6TWM2OD1zNz6x5qCKyrIkgJmwMlQhdk1? NEPhN5UzPTNyOEmxOi=>
Caki-1 Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[3VVlmOTBxMkWvOVAhdk1? MmHGOFghcA>? MknzbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ MUOyOVI4QTF7MR?=
ACHN NYT1bIY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknjNVAwOjVxNUCgcm0> NYDpUGtlPDhiaB?= NFjk[pFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= MoHWNlUzPzlzOUG=
769-P MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXDWphvOTBxMkWvOVAhdk1? MU[0PEBp NXH1OGhHcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny NXHOSYVuOjV{N{mxPVE>
786-O  M{XuWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELGPFMyOC9{NT:1NEBvVQ>? MlzZOFghcA>? NX\5eY5NcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny MmWwNlUzPzlzOUG=
Caki-1 NIexd25CeG:ydH;zbZMhSXO|YYm= MWW1NEBvVQ>? MV20PEBp MUnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? MUGyOVI4QTF7MR?=
ACHN MXnBdI9xfG:|aYOgRZN{[Xl? NWT4PFR6PTBibl2= Mn7oOFghcA>? NHe1coxqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= NVXy[2ZkOjV{N{mxPVE>
769-P MVvBdI9xfG:|aYOgRZN{[Xl? MoPSOVAhdk1? M4nYOFQ5KGh? NG\kb4VqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= NHHSWZYzPTJ5OUG5NS=>
786-O  MV7BdI9xfG:|aYOgRZN{[Xl? NFXaZYs2OCCwTR?= M1npdVQ5KGh? M1zRVYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ NGjwWYQzPTJ5OUG5NS=>
Caki-1 NX\lPIJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37UT|I2NzVyIH7N MYW0PEBp M2T4XGROW09? MlvqbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?= NUjke2V5OjVzN{[zOVQ>
ACHN NF3zSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfqU3EzPS93MDDuUS=> M4Lj[FQ5KGh? Mn;tSG1UVw>? NIXTVlVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni M1PNS|I2OTd4M{W0
769-P MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjRNlUwPTBibl2= M{LHV|Q5KGh? MVTEUXNQ M2DQ[olvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK= NInYSGEzPTF5NkO1OC=>
Caki-1 NIXKNWtEd2yxbomgSo9zdWG2aX;uJGF{e2G7 NWTxUoFCPTBibl2= M1ztVFcuOTRiZB?= MXrEUXNQ MmrHd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> MWmyOVE4PjN3NB?=
ACHN MYTDc4xwdnliRn;ycYF1cW:wIFHzd4F6 MWC1NEBvVQ>? MUC3MVE1KGR? NUnBenZlTE2VTx?= MYjzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> MkDhNlUyPzZ|NUS=
769-P NE\yXnZEd2yxbomgSo9zdWG2aX;uJGF{e2G7 NVf1VoJtPTBibl2= MWW3MVE1KGR? MY\EUXNQ MnrCd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> M{ewSFI2OTd4M{W0
Caki-1 MYXBdI9xfG:|aYOgRZN{[Xl? NXjRNXZIPTBibl2= MkLxOFghcA>? M2nVZ2ROW09? NWrJeI86cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M2fqWVI2OTd4M{W0
ACHN MX7BdI9xfG:|aYOgRZN{[Xl? MlTMOVAhdk1? MUe0PEBp Mn76SG1UVw>? MVrpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MnzqNlUyPzZ|NUS=
769-P MoTCRZBweHSxc3nzJGF{e2G7 M4PaRVUxKG6P Mo\POFghcA>? Ml;ESG1UVw>? MV;pcoR2[2W|IHPlcIwh[XCxcITvd4l{ NFTnTmkzPTF5NkO1OC=>
MDA-MB-231 M3TDWm1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? MU[xNOKhdk1? M{fvRlPDqGR? Mmf1SG1UVw>? NYL1UWV7[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg M4PmZ|I1QDFyNEm3
BT-549 MlqyUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 M3yxTlExyqCwTR?= M2XB[|PDqGR? MWjEUXNQ NYPKRWRY[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg NGTUNZYzPDhzMES5Oy=>
MCF-7  NI\FSYNOd3KyaH;sc4dq[2GuIFPyfZN1[WxiVnnvcIV1KCiFVjmgRZN{[Xl? M3vQNFExyqCwTR?= MnjiN:Kh\A>? NV3qfJdbTE2VTx?= MWHhcJRmenNiY3XscEBud3KyaH;sc4d6yqB? MmPtNlQ5OTB2OUe=
MCF-7 M4S2eWZ2dmO2aX;uJGF{e2G7 MoPtOU02OCCwTR?= M3LIXVI1KGh? M2nRPGROW09? NXLieXhkemWmdXPl[EB1cGVibHX2[Ywhd2ZiZYjwdoV{e2mxbjDv[kBGWs7zLDDQVkBidmRiRn;4RVHDqA>? MX:yOFM3PjRyNx?=
CTS MXzBdI9xfG:|aYOgRZN{[Xl? NUTQWpdVOOLCk{SwJI5OyqB? NUj6cGhNPDhiaB?= Mn[4bY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NUTUVY5NOjR{NES0Nlk>
OCI-AML3  NE[2eplCeG:ydH;zbZMhSXO|YYm= Mkm1NQKBmzRyIH7NxsA> NHS4d4E1QCCq NWTxPY1TcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MknlNlQzPDR2Mkm=
U937 NFf2bmNCeG:ydH;zbZMhSXO|YYm= MVWw5qCUPDBibl5CpC=> NHi1[Vc1QCCq NFG2U|VqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NWD2epJGOjR{NES0Nlk>
PC3 MmDoRZBweHSxc3nzJGF{e2G7 Ml;GNE0yODBibl2= Mnn3NlQwPDhiaB?= M3rKUolv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1Tk[|I1OTZ|MkOw
PC3-AR NEGxb|FCeG:ydH;zbZMhSXO|YYm= MVqwMVExOCCwTR?= NX\afll5OjRxNEigbC=> NVjreVFmcW6mdXPld{BieG:ydH;zbZMhcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NWrTU3lmOjRzNkOyN|A>
PC3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVGzZog{OC1zMECgcm0> MnjDNlQwPDhiaB?= NEW2OVdqdmS3Y3XzJIFk[3WvdXzheIlwdiCxZjDzeYJIOSCyb4D1cIF1cW:w MVGyOFE3OzJ|MB?=
PC3-AR M3nBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\YNE0yODBibl2= M3\0TVI1NzR6IHi= MXvpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJJRp\SCJMl2gdIhie2V? MonkNlQyPjN{M{C=
PC3 MUTGeY5kfGmxbjDBd5NigQ>? MlLmNE0yODBibl2= MYeyOEBp NU\G[pF7e3WycILld5NmeyCneIDy[ZN{cW:wIH;mJIFkfGm4YYTl[EBCXE1uIFHreEBidmRiRYLrNU8zKHC{b4TlbY4> NIf5ZXUzPDF4M{KzNC=>
PC3-AR MW\GeY5kfGmxbjDBd5NigQ>? NWP2Xo9VOC1zMECgcm0> NYnCZXZVOjRiaB?= NGLt[3N{fXCycnXzd4V{KGW6cILld5Nqd25ib3[gZYN1cX[jdHXkJGFVVSxiQXv0JIFv\CCHcnuxM|IheHKxdHXpci=> NWHmZ3VUOjRzNkOyN|A>
OS-RC-2 NVnYUHlWS2WubDDWbYFjcWyrdImgRZN{[Xl? NWW3TnJrOC1zMECwJI5O NXu4ZnR3OjRxNEivO|IhcA>? M3HKeWROW09? Mo\U[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MoTTNlQyPDR5M{e=
OS-RC-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Pnd|UxKG6P NY[z[FZ2PDhiaB?= NUTNT4NMTE2VTx?= MoPYbY5lfWOnczDHNk9OKGG{cnXzeC=> NGXJbpMzPDF2NEezOy=>
OS-RC-2 NGP5[4xCeG:ydH;zbZMhSXO|YYm= NEXORZM2OCCwTR?= MYS0PEBp MYLEUXNQ M{PtZolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MkLGNlQyPDR5M{e=
SK-N-AS MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnKNWkx6oDVOECgcm0> NXnHbIpWPDhiaB?= M363dWlEPTB;MkeuOEBvVQ>? NVnCW4NWOjRyOUi3PVk>
SK-N-DZ MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPuNQKBmzhyIH7N M3HCXVQ5KGh? MXzJR|UxRTJzLkmgcm0> MWSyOFA6QDd7OR?=
SK-N-SH M{C2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmw5qCUQDBibl2= NVHKeYQ4PDhiaB?= M4LGdWlEPTB;N{KuN{BvVQ>? NEfVZZQzPDB7OEe5PS=>
SK-N-BE MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnjbIk{OOLCk{iwJI5O Mke4OFghcA>? NWTOTJRDUUN3ME23OU41KG6P MoDYNlQxQTh5OUm=
SK-N-AS MnmzRZBweHSxc3nzJGF{e2G7 NXrybVBiOOLCk{iwJI5O M{C0SVQ5KGh? MV\wc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= NEGycWEzPDB7OEe5PS=>
SK-N-DZ MkDSRZBweHSxc3nzJGF{e2G7 NUfudpNLOOLCk{iwJI5O M4TwV|Q5KGh? NWHSfFBweG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v MknDNlQxQTh5OUm=
SK-N-SH MWnBdI9xfG:|aYOgRZN{[Xl? NE\Db44x6oDVNECgcm0> MXG0PEBp NVfoVHhqeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v M4\hO|I1ODl6N{m5
SK-N-BE M1nBZmFxd3C2b4Ppd{BCe3OjeR?= MVuw5qCUPDBibl2= M3HvNlQ5KGh? M3rrbpBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> M3T3cVI1ODl6N{m5
SK-N-AS NEX1cnNHfW6ldHnvckBCe3OjeR?= Ml32NQKBmzhyIH7N MXq0PEBp NUPZV4h[cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? NE\HPJAzPDB7OEe5PS=>
SK-N-DZ M4TRe2Z2dmO2aX;uJGF{e2G7 M2\mSFDjiJN6MDDuUS=> NHz3N5o1QCCq M3rodIlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> M{LONFI1ODl6N{m5
SK-N-SH NX7WbmRUTnWwY4Tpc44hSXO|YYm= NUPvNINKOOLCk{SwJI5O NXXTfZA5PDhiaB?= M3LNU4lv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> M4ThZlI1ODl6N{m5
SK-N-BE MYLGeY5kfGmxbjDBd5NigQ>? MVmw5qCUPDBibl2= M1m1PFQ5KGh? NV\TWlZUcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? NFrvTIUzPDB7OEe5PS=>
HCC-LM3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2q5XlEuOTByMDDuUS=> Mo[4NlQwPDhxN{KgbC=> NHH4[opFVVOR MonObY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NIPYT20zPDB7M{m1Oi=>
HepG2 MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrwRmFrOS1zMECwJI5O NVK3XFlQOjRxNEivO|IhcA>? NIXZcZFFVVOR M1rkOolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3PpVlI1ODl|OUW2
SMMC-7721 NVjS[3A5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETzVYgyNTFyMECgcm0> NUTF[YZYOjRxNEivO|IhcA>? Ml3uSG1UVw>? NHrXc2dqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NWHaVo1TOjRyOUO5OVY>
HCC-LM3 NGnBSY1CeG:ydH;zbZMhSXO|YYm= M4rUbFUxKG6P NES2SpM1QCCq MULEUXNQ NWfsfnVvcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl? MmD0NlQxQTN7NU[=
HepG2 NXfTZot{SXCxcITvd4l{KEG|c3H5 NFX6UZI2OCCwTR?= MWC0PEBp NEjoNpdFVVOR NInNRmJqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMhOyxiODDhcoQhQQ>? M2WzeFI1ODl|OUW2
SMMC-7721 M{TRS2Fxd3C2b4Ppd{BCe3OjeR?= MV61NEBvVQ>? NGC5NmI1QCCq MXXEUXNQ NWfmbo1CcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl? MUWyOFA6Ozl3Nh?=
HCC-LM3 NHzvUGZHfW6ldHnvckBCe3OjeR?= NXHBZlFlPTBxMUCwJI5O NH3wVFgzPCCq Mn\rSG1UVw>? M4jaT4Rm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC= MkDhNlQxQTN7NU[=
HepG2 MXvGeY5kfGmxbjDBd5NigQ>? NWTTO40{PTBxMUCwJI5O NUnIXnJvOjRiaB?= NHzRWlRFVVOR NETHNJdl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR|IHHu[EBxNUGtdNMg MVOyOFA6Ozl3Nh?=
SMMC-7721 NELsb|BHfW6ldHnvckBCe3OjeR?= NYq2[4RKPTBxMUCwJI5O MVeyOEBp Mmf2SG1UVw>? MnLk[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?= NXW0SIpLOjRyOUO5OVY>
HCC-LM3 NW\FNWw5TnWwY4Tpc44hSXO|YYm= NInOcIU2OC9zMECgcm0> MVOyOEBp M1qx[GROW09? M2TkboRwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25? NViwWZY1OjRyOUO5OVY>
HepG2 MnXaSpVv[3Srb36gRZN{[Xl? MXO1NE8yODBibl2= M1T4eFI1KGh? NGSyXGVFVVOR MWDkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v NWrVPYZIOjRyOUO5OVY>
SMMC-7721 MmnqSpVv[3Srb36gRZN{[Xl? NUW2R|RqPTBxMUCwJI5O M1jzNlI1KGh? MlXISG1UVw>? MlXU[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>? Mn\iNlQxQTN7NU[=
FaDu MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTrNVAx6oDHbl2= NYnqenluQC9zMD:xNkBp MmTS[Il{eGyjeXXkJIEhe2mpbnnmbYNidnRiYX7kJJBzd2yxbnfl[EBIOi:PIHHydoV{fCCjdDC4JIFv\CBzMvMAiYgheG:|dDDy[Yxm[XOn NGrFVYIzPDB{NkS4Ni=>
FaDu MoLISpVv[3Srb36gRZN{[Xl? M{K2bFExOOLChX7N MXuyM|QwQC9zMjDo M1H1V4lv\HWlZXSgdFIyX2GoMT;DbZAyyqCneIDy[ZN{cW:w NFTH[2ozPDB{NkS4Ni=>
PC-3  MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXmwMVExKM7:TR?= Mlr6NlQwPDhxN{KgbC=> NYnxc4F[cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M2XoZ|I{QTlzMkG2
LNCaP MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjFcYNKOC13IN88US=> NGe2XGgzPC92OD:3NkBp NHLUbYFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGWzRmQzOzl7MUKxOi=>
RWPE-1  M4LYXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MViwMVIxKM7:TR?= MmK2NlQwPDhxN{KgbC=> MVPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M37JUVI{QTlzMkG2
Capan-1 NYe3RZNKTnWwY4Tpc44hSXO|YYm= MnnnNlUwPTBxMUCwJI5O M1fMVFgwOjRxNEigbC=> NX32[482TE2VTx?= MXHkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p NHG0TIczOzl{Mki4Oi=>
L3.6pl M1;TdWZ2dmO2aX;uJGF{e2G7 MYOyOU82OC9zMECgcm0> MVW4M|I1NzR6IHi= NFK2fYZFVVOR M3TGcYRwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne= NU\S[HdLOjN7MkK4PFY>
CFPAC-1  NX7YXHZyTnWwY4Tpc44hSXO|YYm= NVzhUXFIOjVxNUCvNVAxKG6P NYrkc2NEQC9{ND:0PEBp MmOzSG1UVw>? NH;IWXdld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n Mli0NlM6OjJ6OE[=
Capan-1 NWDSUlMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fOc|I2NzVyL{GwNEBvVQ>? NYO2dnpoPDhiaB?= NFuzXHZFVVOR NGPzT3Fz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVLE[plvOjN7MkK4PFY>
L3.6pl NUXi[FZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4njeVI2NzVyL{GwNEBvVQ>? NV\tSXlxPDhiaB?= MoT2SG1UVw>? NXfjTYxCemWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MkPZNlM6OjJ6OE[=
CFPAC-1  MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33OeFI2NzVyL{GwNEBvVQ>? MnrSOFghcA>? NIPIVHdFVVOR M3jJWZJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NWm1WY1OOjN7MkK4PFY>
Capan-1 M2TveWFxd3C2b4Ppd{BCe3OjeR?= Mlq1NlUwPTBxMUCwJI5O MXm0PEBp NH7VcGNFVVOR Ml\QbY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NWnGOpI{OjN7MkK4PFY>
L3.6pl MXLBdI9xfG:|aYOgRZN{[Xl? MmS1NlUwPTBxMUCwJI5O NXHxbnUxPDhiaB?= NY\qfoVYTE2VTx?= MWXpcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MWKyN|kzOjh6Nh?=
CFPAC-1  MYTBdI9xfG:|aYOgRZN{[Xl? M4fYcFI2NzVyL{GwNEBvVQ>? NIHpW|g1QCCq NHj0dWdFVVOR MVHpcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MWOyN|kzOjh6Nh?=
HN22 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPHWGs6OC1{MDDuUS=> M4jERlI1NzR6IHi= M2[5W2ROW09? MXHpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy MVKyN|g4PzJ|NR?=
HSC4  NFvoWW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnsN2IxNTJyIH7N MlfkNlQwPDhiaB?= NY\OeGh[TE2VTx?= NYnBRZc{cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? M4T4XlI{QDd5MkO1
HN22 NXKzZmpWSXCxcITvd4l{KEG|c3H5 NHHkVYUxNTJyIH7N M{Pt[VQ5KGh? MkTZSG1UVw>? NVS1TWd[cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NEf6ToczOzh5N{KzOS=>
HSC4  MlezRZBweHSxc3nzJGF{e2G7 MV:wMVIxKG6P MkTrOFghcA>? MUPEUXNQ NYPLTo1UcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MYSyN|g4PzJ|NR?=
HN22 NGO1XIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfTNE0zOCCwTR?= M4PuWVQ5KGh? MWLEUXNQ NVf1PJhocW6mdXPld{BIOSCyaHHz[UBk\WyuIHP5Z4xmKGG{cnXzeOKh M1XBT|I{QDd5MkO1
HSC4  MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnPPIcxNTJyIH7N NXviOZBEPDhiaB?= NGXGXnJFVVOR MnHFbY5lfWOnczDHNUBxcGG|ZTDj[YxtKGO7Y3zlJIFzemW|dNMg M2XENFI{QDd5MkO1
HN22 M3zkfGZ2dmO2aX;uJGF{e2G7 MoPLNE0zOCCwTR?= MVS0PEBp NVnLS5RjTE2VTx?= MYnzeZBxemW|c3XzJHNxOSCneIDy[ZN{cW:wwrC= NHvLSokzOzh5N{KzOS=>
HSC4  NWTuW4IyTnWwY4Tpc44hSXO|YYm= MU[wMVIxKG6P NVfDbFhsPDhiaB?= Moj1SG1UVw>? MYfzeZBxemW|c3XzJHNxOSCneIDy[ZN{cW:wwrC= M4q5flI{QDd5MkO1
Cal62 NGrsdVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi0TWM2OD1|MzFCtUA1KG6P M3XDN|I{QDJ2ME[0
Hth7 MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ywPGlEPTB;MUWgxtEhOiCwTR?= M{X2d|I{QDJ2ME[0
Hth83 MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTN2INMxJFUhdk1? M4j1UFI{QDJ2ME[0
C643 NX7Q[JJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\jTWM2OD15MTFCtUAyOCCwTR?= NWrXXZN4OjN6MkSwOlQ>
SW1736 NF6wOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T4SWlEPTB;M{WgxtEhQCCwTR?= MVuyN|gzPDB4NB?=
T241 NEjLcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjETWM2OD14NTFCtUA4KG6P MkHhNlM5OjRyNkS=
T351 MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1z6cmlEPTB;NUCgxtEhOTBibl2= MmfNNlM5OjRyNkS=
BHP2-7 MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37P[mlEPTB;M{egxtEhPiCwTR?= NXvxPFBsOjN6MkSwOlQ>
T238 M{fNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTFuNUCwJOKyKDJyMDDuUS=> NXf0ToFJOjN6MkSwOlQ>
HCT8 NWfFb3JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLCZ5ZpPzJiaB?= MVTEUXNQ NWHxNZN2UUN3ME2xNk466oDLwsJihKkyNjlibl2= NE\IN4MzOzJ7OUO4PC=>
H630 NWS5RpBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP1Wng4OiCq M1:4PGROW09? MXHJR|UxRTF{LkVihKnDueLCiUOuNUBvVQ>? MmDhNlMzQTl|OEi=
cH630 5-FU-res M3PTcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDOZ4Q4OiCq NHjzb3NFVVOR MnPvTWM2OD1zNT615qCKyrIkgJmxMlIhdk1? M3XUWlI{Ojl7M{i4
HCT116 MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\4dFczKGh? M3q4[WROW09? MlH1TWM2OD1zMD635qCKyrIkgJmyMlIhdk1? NWTO[YpVOjN{OUmzPFg>
HCT116 p53−/− NET3cJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPWepY4OiCq NWW1flJyTE2VTx?= NEm2fJVKSzVyPUiuOwKBkcLz4pEJNU44KG6P MnX5NlMzQTl|OEi=
dHCT116 p21−/− M4HSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn5bJE4OiCq M1\RbmROW09? NVfIS4w5UUN3ME21MlnjiIoEsfMAjVEvOyCwTR?= M3nUSlI{Ojl7M{i4
HT29 M1HvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe4O|IhcA>? MorxSG1UVw>? MWDJR|UxRTF4LkRihKnDueLCiUKuN{BvVQ>? MlnmNlMzQTl|OEi=
LoVo M4fwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\HfHBJPzJiaB?= MWfEUXNQ NI\wOHBKSzVyPUWuNgKBkcLz4pEJNE43KG6P NH2zSG8zOzJ7OUO4PC=>
RKO MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPOeJM4OiCq MVnEUXNQ M{\1Z2lEPTB;Nz655qCKyrIkgJmyMlIhdk1? MV[yN|I6QTN6OB?=
SW480 NX7hSnlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVW3NkBp Mnn5SG1UVw>? Mlf6TWM2OD1zNz615qCKyrIkgJmwMlghdk1? MWSyN|I6QTN6OB?=
eSW620 NG\DXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXS3NkBp NFLZXXVFVVOR MXfJR|UxRTlwMfMAjeKy6oDLMj6xJI5O MVKyN|I6QTN6OB?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DNMT1 / EZH2; 

PubMed: 19279403     


Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control.

caspase-8 / cleaved caspase-8 / Sp1; 

PubMed: 27738323     


The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. 

c-Myc / IRF4; 

PubMed: 27738323     


RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting.

Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; 

PubMed: 28915627     


Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1.

RAD51 / BRCA1 / CHK1 / RPL13a; 

PubMed: 24244429     


CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells.

H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; 

PubMed: 31071955     


Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.

19279403 27738323 28915627 24244429 31071955
Immunofluorescence
Synaptophysin / NACM; 

PubMed: 28915627     


Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm.

α-tubulin / Acetyl-α-tubulin; 

PubMed: 29983882     


CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm.

BiP; 

PubMed: 23544167     


Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

ATF4; 

PubMed: 23544167     


HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

IRE1α / S724-IRE1α; 

PubMed: 23544167     


Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

28915627 29983882 23544167
Growth inhibition assay
Cell viability; 

PubMed: 27738323     


The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.

27738323
In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Formulation: Dextrose 5% in water
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
in solvent
Synonyms NVP-LBH589
Smiles CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=C([NH]1)C=CC=C3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03632317 Withdrawn Drug: Panobinostat|Drug: Everolimus Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center October 2019 Phase 2
NCT03982134 Withdrawn Drug: PDR001|Drug: Panobinostat Melanoma|Non Small Cell Lung Cancer Muhammad Furqan|Novartis Pharmaceuticals|University of Iowa September 2019 Phase 1
NCT03515915 Recruiting -- Patients With Recurrent or Refractory Multiple Myeloma University Hospital Montpellier|Poitiers University Hospital April 23 2018 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID